Skip to main content
Clinical Trials/CTRI/2024/03/064128
CTRI/2024/03/064128
Not yet recruiting
Phase 4

Evaluation of two different doses of bupivacaine (0.25% and 0.125%)20ml in US guided pericapsular nerve group block for ease of positioning for spinal anaesthesia during hip surgery - Nil

Dr RPGMC Kangra Tanda0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: O- Medical and Surgical
Sponsor
Dr RPGMC Kangra Tanda
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Dr RPGMC Kangra Tanda

Eligibility Criteria

Inclusion Criteria

  • Patient scheduled for hip surgeries under subarachnoid block who are American Society of Anaesthesiologist (ASA) physical status I \-III and consenting

Exclusion Criteria

  • 1\.Fractures older than 2 weeks
  • 2\.Patients who were unwilling
  • 3\.Patients having no pain while sitting
  • 4\.Any bleeding disorder and patient on anticoagulants
  • 5\.Neurological and musculoskeletal disease
  • 6\.Local infection at the injection site
  • 7\.History of allergy to local anaesthetic and signs of allergy to lignocaine test dose

Outcomes

Primary Outcomes

Not specified

Similar Trials